Ambrx Biopharma American Stock Z Score
Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
Ambrx |
Ambrx Biopharma American Company Z Score Analysis
Ambrx Biopharma's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
Current Ambrx Biopharma Z Score | 85.23 |
Most of Ambrx Biopharma's fundamental indicators, such as Z Score, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ambrx Biopharma American is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
| |||||||
| |||||||
| |||||||
| |||||||
|
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
CompetitionIn accordance with the company's disclosures, Ambrx Biopharma American has a Z Score of 85. This is much higher than that of the Biotechnology sector and notably higher than that of the Health Care industry. The z score for all United States stocks is notably lower than that of the firm.
Ambrx Z Score Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ambrx Biopharma's direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ambrx Biopharma could also be used in its relative valuation, which is a method of valuing Ambrx Biopharma by comparing valuation metrics of similar companies.Ambrx Biopharma is currently under evaluation in z score category among its peers.
Ambrx Fundamentals
Return On Equity | -0.37 | |||
Return On Asset | -0.19 | |||
Operating Margin | (483.51) % | |||
Current Valuation | 1.56 B | |||
Shares Outstanding | 63.29 M | |||
Shares Owned By Insiders | 2.09 % | |||
Shares Owned By Institutions | 97.91 % | |||
Number Of Shares Shorted | 1.16 M | |||
Price To Earning | 0.19 X | |||
Price To Book | 7.31 X | |||
Price To Sales | 432.96 X | |||
Revenue | 4.09 M | |||
Gross Profit | 7.4 M | |||
EBITDA | (61.75 M) | |||
Net Income | (67.06 M) | |||
Cash And Equivalents | 110.89 M | |||
Cash Per Share | 2.87 X | |||
Total Debt | 11.98 M | |||
Debt To Equity | 0.09 % | |||
Current Ratio | 4.70 X | |||
Book Value Per Share | 3.85 X | |||
Cash Flow From Operations | (57.7 M) | |||
Short Ratio | 1.21 X | |||
Earnings Per Share | 0.42 X | |||
Price To Earnings To Growth | (0.15) X | |||
Target Price | 28.5 | |||
Number Of Employees | 87 | |||
Beta | -2.36 | |||
Market Capitalization | 1.77 B | |||
Total Asset | 146.98 M | |||
Retained Earnings | (291.63 M) | |||
Working Capital | 73.92 M | |||
Z Score | 85.23 | |||
Net Asset | 146.98 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Other Consideration for investing in Ambrx Stock
If you are still planning to invest in Ambrx Biopharma American check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ambrx Biopharma's history and understand the potential risks before investing.
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |